Gastric cancer is the third most common cause of death from cancer in the world and 25 it remains difficult to cure in Western countries, primarily because most patients present 26 with advanced disease. Currently, CEA, CA50 and CA72-4 are commonly used as 27 tumor markers for gastric cancer by immunoassays. However, the drawback and 28 conundrum of immunoassay are the unceasing problem in standardization of quality of 29 antibodies and time/effort for the intensive production. Therefore, there is an urgent 30 need for the development of a standardized assay to detect gastric cancer at the early 31 stage.
133
throughput sequencing technology and then measured their affinity by fluorescence 134 spectroscopy. Their dissociation constants ranged from 16.5 to 156nM which 135 implicates high affinities between the aptamers and the antigens. Intriguingly, the 136 predicted secondary structures of RNA aptamers from each antigen showed significant DNA oligos and antigens 150 An initial DNA library that had a random 30-nucleotide sequence (N30) in between 151 as the viable region, were deliberately designed and ordered (Life Technologies) as the 152 template (Fig 1a) . The length of N30 sequence is 82 nucleotides (nt), including a T7 153 promoter at the 5'-end, a BamH I and a Hind III restriction site flanking as the boundary, 154 and a barcode sequence at the 3'-end for discrimination in sequencing. Gastrointestinal 155 cancer biomarkers (Human source, high purity) were respectively purchased: CEA 156 (Abcam), CA50 (BIO-RAD), and CA72-4 (BIO-RAD). were accumulated to a certain level, respectively.
291
In order to assess the sequences of enriched RNA aptamers after selection, the 292 purified aptamers were reverse transcribed, amplified, overhangs addition at 3' end and 293 subcloned into the TA vector. For each antigen, 15-20 single colonies were randomly 294 picked for sequencing. As shown in Table 1 , the consensus sequences (*, **) were 295 successfully identified in all three RNA pools, indicating the feasibility of the 296 enrichment methodology and the possibility to subject for high-throughput sequencing. Highly abundant aptamers revealed by high-throughput sequencing (HTS) 301 Since SANGER sequencing could only provide limited data, we adopted the high- Table 2 , the distribution of the identified aptamers were 308 shown in Fig 2. In our results, the consensus sequences revealed by SANGER 309 sequencing were all found in top 5 ranking sequences in HTS. In order to observe the 310 profile of the aptamers in each case, the distribution of the aptamers was plotted as a 311 pie chart. As shown in Fig 2 and RNA aptamers, CEA A01, A02; CA50 A01, A02, and CA72 A01, A02 (Table 3) (Table 4) . aptamers showed positive fluorescent signal same as CEA antibody (Fig 4) whereas retained 85% and 87% (Fig 5a) , indicating the transfection alone did not affect their 368 growth and viability. On the other hand, viability of aptamer-treated cells greatly 369 decreased to a range from 52% to 68% of total number of cell (Fig 5a) . Moreover, study 370 on the rate of cell growth demonstrated 2-3 folds suppression of aptamer-treated cells 371 compared with WT after 3 days (Fig 5b) , suggesting that the growth of LS174T cells 372 was also inhibited by the aptamers. 
Discussion

378
To tackle the limitations of using immunoassays for the detection of tumor markers, 379 we established the SELEX method incorporated with high-throughput sequencing by 380 ion Torrent (Ion PGM™ system) to screen RNA aptamers from a random RNA pool. the cancer biomarkers. The mechanism of the inhibitory effect on cell viability and 411 growth by RNA aptamers is unclear and yet to be determined.
412
Taken together, this study demonstrates that SELEX incorporated with HTS is a 413 promising and powerful tool to screen aptamers for various targets. To obtain qualified several modifications could be considered: to truncate ribonucleic acids in block to 418 simplify the aptamer and specify the core region for RNA-protein interactions; to 419 individually substitute / delete / insert a particular ribonucleic acid in the core region of 420 aptamer to improve its specificity; to chemically modify particular ribonucleic acid(s) 421 of aptamer with locked nucleic acid (LNA) to decrease its susceptibility to nucleases 422 and increase its stability for long-term storage. Indeed, it is possible that such aptamers 423 would become applicable in clinical applications or even therapeutics in the near future 424 with better sensitivity and specificity, and without the limitations of immunoassays. 
